NEW YORK, May 19, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of ImmunoCellular Therapeutics, Ltd. securities (NYSE MKT:IMUC) from May 1, 2012 through December 11, 2013, inclusive (the “Class Period”). The lawsuit seeks to recover damages for ImmunoCellular investors under the federal securities laws.
To join the ImmunoCellular class action, go to http://rosenlegal.com/cases-1115.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The complaint alleges that defendants during the Class Period made false and misleading statements and/or failed to disclose that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote ImmunoCellular, which led the market to believe that ImmunoCellular’s clinical studies for its product candidate ICT-107 was going well. As a result of this scheme, ImmunoCellular’s share price was artificially inflated. On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against ImmunoCellular, as well as other individuals and entities, for engaging in stock promotion schemes.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 30, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1115.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Google Halts UK YouTube TV Measurement Service After Legal Action
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors
The Maire - EuroChem Case: Three Lessons for Global Business
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 



